DePuy Orthopaedics, a subsidiary of Johnson & Johnson, has acquired the US-based BioMedical Enterprises (BME).
Based in San Antonio of Texas, BME is engaged in the manufacturing of nitinol orthopaedic implants for small bone fixation.
The company has developed implants for the treatment of bunions, hammertoes and other foot and ankle deformities, as well as hand and wrist deformities.
It also produces nitinol metal implants for musculoskeletal fixation and memory metal implants for bone fixation.
The acquisition is expected to expand Johnson & Johnson’s medical device portfolio for use in the elective extremity procedures, helping in offering complete solution for foot and ankle and hand and wrist specialists.
DePuy Synthes company group chairman Ciro Römer said: "BME’s technology is an excellent complement to our comprehensive portfolio of solutions that spans all of orthopaedics.
"The BME portfolio will be integrated into our trauma platform, where we will be able to expand the availability of these solutions, increase the pace of innovation in this area, and reach more patients around the world."
DePuy Synthes produces products for the joint reconstruction, trauma, neurological, craniomaxillofacial and spinal surgery.
It also manufactures implants and instruments for the surgical treatment of orthopaedic deformities and tumor diseases.
Image: Johnson & Johnson headquarters in New Brunswick, New Jersey. Photo: courtesy of Nikopoley.